US Health Partners, LLC
-76%
est. 2Y upside i
Rank
#2686
Sector
Healthcare Services
Est. Liquidity
~3Y
Data Quality
Data: LowUS Health Partners, LLC presents a risky equity opportunity for a job seeker.
Last updated: March 10, 2026
US Health Partners successfully expands its national cardiovascular network, integrating advanced AI-driven analytics to demonstrate superior patient outcomes and cost efficiencies. This leads to significant payor contracts and a strategic acquisition by a large healthcare system or private equity firm at a $250M valuation, representing a 2.5x return on the assumed current valuation.
The company continues to grow steadily within its niche, adding physician partners and refining its service offerings. It achieves moderate market penetration in its SAM, leading to an acquisition at a $175M valuation, a 1.75x return on the assumed current valuation, as it becomes an attractive bolt-on for a larger healthcare services provider.
Intense competition from larger incumbents and slower-than-expected adoption of its specialized cardiovascular solutions limit growth. The small team struggles to scale, leading to a down round or a distressed sale at a $40M valuation, resulting in a significant loss for common stock holders due to liquidation preferences.
Preference Stack Risk
severeAssuming $50M in total funding and a $100M current valuation, the investor take ratio is 50%, indicating substantial liquidation preferences ahead of common stock.
Dilution Risk
highAs a Series C company, further funding rounds are likely before an exit, which will lead to additional dilution for existing equity holders.
Secondary Liquidity
noneFor a company of this size and stage, active secondary markets or tender offers for employee equity are highly unlikely.
Questions to Ask at the Interview
Strategic questions based on US Health Partners, LLC's data — designed to show you've done your homework.
- 1
“Given the competitive landscape with large incumbents like UnitedHealth and CVS Health, how does US Health Partners plan to scale its national network and maintain its competitive moat in cardiovascular care?”
- 2
“With an employee count of 6 as of July 2024, how does the company plan to manage the operational demands and growth trajectory expected of a Series C-funded organization?”
- 3
“Could you provide more clarity on the company's total funding raised to date and the current valuation, and how this impacts the potential for common stock holders in various liquidity scenarios?”
Community
Valuation Sentiment
Our model estimates -76% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.